Humalog Mix 25: Compound Profile
Humalog Mix 25 is a biphasic insulin suspension manufactured by Eli Lilly, containing 25% insulin lispro (rapid-acting) and 75% insulin lispro protamine suspension (intermediate-acting). This pharmaceutical-grade preparation serves as a critical tool for investigating glucose metabolism, insulin kinetics, and diabetes pathophysiology in controlled laboratory environments. At Stroid UK Shop, researchers can access authentic Eli Lilly formulations for comprehensive endocrine studies.
Laboratory Applications
This insulin formulation enables researchers to examine biphasic insulin action patterns, studying both immediate glucose uptake mechanisms and sustained metabolic responses. The 100IU cartridge format provides standardised dosing for experimental protocols investigating insulin receptor binding, glucose transporter function, and cellular glucose utilisation pathways. Research applications include pharmacokinetic studies, comparative insulin analogue evaluation, and diabetes mellitus model development in laboratory settings. Scientists exploring metabolic dysfunction can complement their insulin studies with research from our general health and insulin category. Additionally, researchers investigating hormonal interactions may find value in exploring our SARMs collection for comparative endocrine studies, while those examining metabolic signalling pathways can access our peptides range for comprehensive metabolic research protocols.
Technical Specifications
| Parameter | Specification |
|---|---|
| Concentration | 100 units/mL |
| Composition | 25% Insulin Lispro, 75% Insulin Lispro Protamine |
| Manufacturer | Eli Lilly and Company |
| Presentation | Prefilled cartridges |
| Storage Conditions | 2-8°C, protect from light |
| Molecular Formula | C₂₅₄H₃₇₇N₆₅O₇₆S₆ (insulin lispro) |
| Molecular Weight | 5808 Da |
| CAS Number | 133107-64-9 |
Research Use Compliance
This product is supplied exclusively for in-vitro research applications and laboratory studies. Humalog Mix 25 is not intended for human consumption, therapeutic use, or any form of self-administration. Researchers must maintain appropriate laboratory conditions, follow institutional biosafety protocols, and ensure proper storage at 2-8°C to preserve insulin stability. All experimental work must be conducted under qualified scientific supervision with appropriate ethical approvals for the intended research applications.
